ROS-Responsive Nanomedicine: Towards Targeting the Breast Tumor Microenvironment
- PMID: 33297907
- DOI: 10.2174/0929867328666201209100659
ROS-Responsive Nanomedicine: Towards Targeting the Breast Tumor Microenvironment
Abstract
The breast tumor microenvironment (TME) promotes drug resistance through an elaborated interaction of TME components mediated by reactive oxygen species (ROS). Although there is massive accumulation of data concerning the targeting of the ROS, little is known about the ROS-responsive nanomedicine for targeting breast TME. This review submits the ROS landscape in breast TME, including ROS biology, ROS mediated carcinogenesis, and reprogramming of stromal and immune cells of TME. We also discussed ROS-based precision strategies for imaging TME, including molecular imaging techniques with advanced probes, multiplexed methods, and multi-omic profiling strategies. ROS-responsive nanomedicine also describes various therapies, such as chemo- dynamic, photodynamic, photothermal, sono-dynamic, immune, and gene therapy for BC. We expound ROS-responsive primary delivery systems for chemotherapeutics, phytochemicals, and immunotherapeutics. This review also presents recent updates on nanotheranostics for simultaneous diagnosis and treatment of BCs. We assume that a review on this advancing field will be beneficial to the development of ROS-based nano-theranostics for BC.
Keywords: Breast cancer; ROS mediated carcinogenesis.; ROS biology; nanotechnology; precision medicine; tumor microenvironment.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Reactive oxygen species (ROS): Critical roles in breast tumor microenvironment.Crit Rev Oncol Hematol. 2021 Apr;160:103285. doi: 10.1016/j.critrevonc.2021.103285. Epub 2021 Mar 11. Crit Rev Oncol Hematol. 2021. PMID: 33716202 Review.
-
Efficacy-shaping nanomedicine by loading Calcium Peroxide into Tumor Microenvironment-responsive Nanoparticles for the Antitumor Therapy of Prostate Cancer.Theranostics. 2020 Aug 2;10(21):9808-9829. doi: 10.7150/thno.43631. eCollection 2020. Theranostics. 2020. PMID: 32863961 Free PMC article.
-
Recent advances of redox-responsive nanoplatforms for tumor theranostics.J Control Release. 2021 Apr 10;332:269-284. doi: 10.1016/j.jconrel.2021.02.030. Epub 2021 Mar 1. J Control Release. 2021. PMID: 33662455 Review.
-
Tumor microenvironment-responsive dynamic inorganic nanoassemblies for cancer imaging and treatment.Adv Drug Deliv Rev. 2021 Dec;179:114004. doi: 10.1016/j.addr.2021.114004. Epub 2021 Oct 15. Adv Drug Deliv Rev. 2021. PMID: 34662672 Review.
-
Nanomedicine-based strategies to target and modulate the tumor microenvironment.Trends Cancer. 2021 Sep;7(9):847-862. doi: 10.1016/j.trecan.2021.05.001. Epub 2021 Jun 3. Trends Cancer. 2021. PMID: 34090865 Review.
Cited by
-
Metabolic reprogramming in cancer and senescence.MedComm (2020). 2025 Mar 4;6(3):e70055. doi: 10.1002/mco2.70055. eCollection 2025 Mar. MedComm (2020). 2025. PMID: 40046406 Free PMC article. Review.
-
Quercetin as a multi-targeted therapeutic agent in breast cancer: molecular targets and therapeutic potential.Med Oncol. 2025 Jul 22;42(8):365. doi: 10.1007/s12032-025-02907-x. Med Oncol. 2025. PMID: 40694163 Review.
-
Nrf2 mediates the effects of shionone on silica-induced pulmonary fibrosis.Chin Med. 2024 Jun 19;19(1):88. doi: 10.1186/s13020-024-00947-5. Chin Med. 2024. PMID: 38898509 Free PMC article.
-
Nanoplatform-Mediated Autophagy Regulation and Combined Anti-Tumor Therapy for Resistant Tumors.Int J Nanomedicine. 2024 Jan 26;19:917-944. doi: 10.2147/IJN.S445578. eCollection 2024. Int J Nanomedicine. 2024. PMID: 38293604 Free PMC article. Review.
-
A bibliometric analysis of drug resistance in immunotherapy for breast cancer: trends, themes, and research focus.Front Immunol. 2024 Aug 12;15:1452303. doi: 10.3389/fimmu.2024.1452303. eCollection 2024. Front Immunol. 2024. PMID: 39188717 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources